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Aims We aimed to evaluate the incremental value of high-sensitive troponin T (hsTnT) for risk prediction prior to
non-cardiac surgery in comparison with the established revised cardiac index.
Methods
and results
In this prospective, international multicentre observational study, 979 patients prior to non-cardiac surgery were en-
rolled. The endpoints were in-hospital mortality, the combination of death, acute myocardial infarction, cardiac arrest,
cardio-pulmonary resuscitation, and acute decompensated heart failure.
Twenty-five patients (2.6%) deceased and 36 (3.7%) of the patients experienced the combined endpoint. Cardiac
markers were elevated in those patients who died when compared with survivors (hsTnT: 21 ng/L vs. 7 ng/L;
P, 0.001; NT-proBNP: 576 pg/mL vs. 166 pg/mL; P, 0.001). Applying a cut-off for hsTnT of 14 ng/L and for
NT-proBNP of 300 pg/mL, those patients with elevated hsTnT had a mortality of 6.9 vs. 1.2% (P, 0.001) and
with elevated NT-proBNP 4.8 vs. 1.4% (P ¼ 0.002). The highest AUC of the ROC curve was found for hsTnT as
a predictor for mortality of 0.809. In a multivariate Cox regression analyses, hsTnT was the strongest independent
predictor for the combined endpoint [HR 2.6 (95% CI: 1.3–5.3); P ¼ 0.01].
Conclusion High-sensitive troponin T provides strong prognostic information in patients undergoing non-cardiac surgery incre-
mental to the widely accepted revised cardiac index.
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Introduction
Non-cardiac surgical procedures are frequently performed in
European countries. Approximately 1.5% of the population are
undergoing major surgical procedures annually.1
However, surgical interventions are associated with relevant car-
diovascular morbidity and mortality. Data on cardiac outcome can
be derived from a few large-scale clinical trials and registries that
have been undertaken in patients undergoing non-cardiac surgery
with major complications rate varying from 1.7 to 3.5%.2– 5
In most cases, non-cardiac surgery is performed as an elective
intervention rendering sufficient time for peri-operative risk assess-
ment. Currently, several clinical risk indices are applied. The most
common ones are the cardiac risk index from Goldman et al., the
modified risk index from Detsky et al. and most recently intro-
duced the revised cardiac risk index from Lee et al.6– 8 Further
tools for risk stratification have been provided by the ACC/AHA
guidelines on peri-operative cardiovascular evaluation for non-
cardiac surgery and by the American Society of Anaesthesiologists
(ASA).9
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Cardiac markers, namely troponins and B-type natriuretic pep-
tides (BNPs), have been recognized as powerful biomarkers
reflecting myocardial injury, respectively, myocardial stress as a
consequence of a variety of underlying pathologies such as heart
failure, coronary artery disease, and valvular heart disease. There
is convincing evidence from a great number of studies that BNP
and NT-proBNP provide strong prognostic information in patients
across a broad spectrum of cardiovascular disorders as well as in
apparently healthy individuals.10,11
Cardiac-specific troponins are the gold standard for the diagnosis
of acute myocardial infarction for several years.12 However more
recently, with the introduction of the new high-sensitive troponin
assays, there is growing evidence, that troponins are also elevated
in patients with various cardiovascular diseases, such as heart
failure or stable coronary heart disease, reflecting minor myocardial
injury and thus providing prognostic information.13,14
Therefore, it was the aim of our study to evaluate the usefulness
of cardiac troponin T (TnT) measured by a new high-sensitive
troponin T assay (hsTnT) for risk stratification of patients undergo-
ing non-cardiac surgery in comparison with an established clinical
risk index and NT-proBNP.
Methods
Patients
The study was conducted as an international multicentre, observation-
al study including patients undergoing major non-cardiac surgery. A
total of 979 patients were recruited between 2006 and 2009 from
eight hospitals located in Germany, Switzerland, Serbia, and Spain.
Inclusion criteria were major non-cardiac surgery (abdominal, uro-
logical, orthopaedic, gynaecologic, neck surgery, and vascular
surgery) in general anaesthesia, an age .55 years and at least one of
the following cardiovascular risk factors—diabetes mellitus, hyperten-
sion, hyperlipidaemia, active smoking, or a family history of cardiac
disease. Exclusion criteria were emergent surgery and the disability
to understand or to sign informed consent.
All the patients included into the study signed informed consent,
which included biomarker analyses. The study has been approved by
the local ethical boards of the participating centres.
Clinical endpoints
As primary endpoint all-cause mortality and the combination of all
cause mortality, acute myocardial infarction, cardiac arrest or ventricu-
lar fibrillation, cardio-pulmonary resuscitation, and acute decompen-
sated heart failure during hospitalisation were pre-defined. As
secondary endpoints, total hospital stay and requirement of intensive
care treatment were assessed. The first occurring event and the
time until this event have been assessed. For the mortality analyses,
only death and the time until death has been evaluated.
Endpoint assessment was carried out according to clinical standards
of the respective centres. The diagnosis of peri- or post-operative
myocardial infarction was made on the basis of the universal definition
of myocardial infarction.12 Briefly, an elevated troponin level with a rise
and fall pattern together with clinical signs of myocardial ischaemia was
considered as myocardial infarction.
Surgical procedures
Patients undergoing major non-cardiac surgery were included. Proce-
dures had to be performed under general anaesthesia. Surgical
procedures were performed according to clinical standards of the re-
spective hospitals. A list of the different kinds of surgical procedures
performed is presented in Table 1.
Revised cardiac index (Lee index)
We calculated the revised cardiac risk index (Lee index) as described
in detail previously.8 Briefly, one point was assigned to each of the fol-
lowing factors: a history of CAD, a history of cerebrovascular disease,
heart failure, insulin-dependent diabetes mellitus, impaired renal func-
tion, and high-risk type of surgery.
Laboratory assessment
Blood samples were taken within 7 days prior to surgery. Samples
were taken from an antecubital vein in tubes without additives and
processed immediately. Serum was separated and frozen at 2708C
until analyses. All analyses were performed after the end of the recruit-
ing phase at the pre-defined core laboratories at the University of
Basel and at the Kerckhoff Heart and Thorax Center in Bad
Nauheim. The investigators at the different centres were blinded to
the biomarker results.
Cardiac TnT was measured by a newly developed high-sensitive
electrochemiluminescence-immunoassay (hsTnT) on an Elecsys analyz-
er (Roche Diagnostics, Mannheim, Germany). The lower limit of detec-
tion for this assay is 3 ng/L, the 99th percentile of a healthy reference
population is 14 ng/L, and the concentration with a coefficient of vari-
ation (CV) ,10% is 13 ng/L. NT-proBNP was measured by an
electrochemiluminescence-immunoassay (Elecsys proBNP, Roche
Diagnostics, Mannheim, Germany). The analytical range extends from
5 to 35 000 pg/mL. The total CV was 3.3% (n ¼ 28) at a level of
252.6 pg/mL and 3.7% (n ¼ 25) at a level of 6130.8 pg/mL of
NT-proBNP.
Statistics
All results for continuous variables are expressed as means+ SD.
Skewed variables are expressed as median and inter-quartile range.
For group wise comparisons, the Mann–Whitney test (two-groups),
the Kruskal–Wallis test (n-groups), Student’s t-test (two-groups), or
one-way ANOVA (n-groups) were used as appropriate. For categorical
variables, Fisher’s exact test or the x2 test were used. To evaluate test
performance of NT-proBNP, hsTnT and the Lee index as predictors
for mortality, respectively, the combined endpoint the area under
the curve (AUC) of the receiver operating characteristics curve
(ROC) has been calculated. Hazard ratios for all clinical variables
were calculated by univariate Cox regression analyses. Multivariate
Cox regression analysis was performed for the combined endpoint in-
cluding the four strongest variables in the univariate analyses with P,
0.1 in the univariate Cox regression analyses. All tests were performed
two sided and a significance level of P, 0.05 was considered to indi-
cate statistical significance. For all statistical analyses, the statistical soft-
ware SPSS 10.0 (Statistical Package for the Social Sciences, Chicago, IL,
USA) for Windows was used.
Results
Baseline characteristics of the patients are presented in Table 1. A
total of 979 patients have been recruited, 46% females, mean age
69 years. A history of CAD, defined as prior bypass surgery, cor-
onary intervention or myocardial infarction, was present in 25% of
the patients. The majority of patients (57%) had two or more car-
diovascular risk factors and 87% of the patients were under
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cardiovascular medical treatment. A Lee index of 0 was present in
277 (28%), of 1 in 450 (46%), of 2 in 187 (19%), and ≥3 in 65 (7%)
patients.
Patients were hospitalized for a median period of 11 (IQR:
7–17) days. During this period 25 (2.6%) patients died and 36
(3.7%) patients experienced the combined endpoint (1 patient
with acute myocardial infarction, 4 patients with ventricular fibril-
lation, 12 patients requiring CPR, 9 patients with acute decompen-
sated heart failure, and 10 patients died without any preceding
endpoint).
Patients who deceased had more frequently pre-existing angina
pectoris, a history of arterial hypertension, a pre-medication of
nitrates or oral anticoagulation, a higher Lee index, hsTnT
.14 ng/L, and NT-proBNP ≥300 pg/mL.
The type of surgery and the mortality rates are presented in
Table 2. More than half of the patients underwent either vascular
or abdominal surgery.
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Table 1 Baseline characteristics
All patients Survivors Deceased P-value survivors vs. deceased
n (%) 979 954 (97.4) 25 (2.6)
Gender (female) n (%) 447 (46) 440 (46) 7 (28) 0.102
Age (years) AM+ SD 69+8 69+8 68+9 0.788
BMI (kg/m2) median (IQR) 27 (24–30) 27 (24–30) 27 (24–30) 0.493
CAD, n (%) 246 (25) 238 (25) 8 (32) 0.483
Dyspnoea (NYHA II–IV), n (%) 293 (30) 281 (30) 12 (48) 0.074
Angina pectoris (CCS II– III) n (%) 106 (11) 99 (10) 7 (28) 0.013
Atrial fibrillation, n (%) 74 (7.6) 71 (7.4) 3 (12) 0.927
Diabetes mellitus, n (%) 258 (27) 251 (26) 7 (28) 0.821
Insulin dependent, n (%) 77 (7.9) 74 (7.7) 3 (12) 0.716
Hypertension, n (%) 860 (88) 843 (88) 18 (72) 0.023
Hyperlipidaemia, n (%) 334 (34) 328 (34) 6 (24) 0.548
Active smoker, n (%) 250 (26) 242 (25) 8 (32) 0.486
Aspirin/clopidogrel, n (%) 435 (44) 421 (44) 14 (56) 0.308
Beta-blocker, n (%) 472 (48) 462 (48) 10 (40) 0.426
ACE inhibitor/AT-antagonist, n (%) 582 (59) 569 (60) 13 (52) 0.537
Diuretics, n (%) 303 (31) 293 (31) 10 (40) 0.380
Nitrates, n (%) 98 (10) 91 (9.5) 7 (28) 0.009
Anticoagulation, n (%) 89 (9) 83 (9) 6 (24) 0.02
Lee index
0 n (%) 277 (28) 275 (29) 2 (8) 0.010
1 n (%) 450 (46) 439 (46) 11 (44)
2 n (%) 187 (19) 178 (19) 9 (36)
≥3 n (%) 65 (7) 62 (7) 3 (12)
Hb (g/dL) median (IQR) 13.6 (12.4–14.7) 13.6 (12.5–14.7) 13.1 (11.7–14.7 0.268
Creatinine (mg/dL) median (IQR) 0.9 (0.76–1.1) 0.90 (0.76–1.1) 0.97 (0.81–1.2) 0.299
hs-TNT (ng/L) median (IQR) 7 (3–14) 7 (3–13) 21 (12–33) ,0.001
NT-proBNP (pg/mL) median (IQR) 171 (79–439) 166 (77–428) 576 (271–2119) ,0.001
hsTnT .14 ng/L, n (%) 233 (24) 217 (23) 16 (64) ,0.001
NT-proBNP .300 pg/mL, n (%) 335 (34) 319 (33) 16 (64) 0.002
n, numbers; IQR, inter-quartile range; BMI, body mass index; CAD, coronary artery disease.
Baseline data of the patients according to survival status.
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Table 2 Type of surgery and mortality
n (%) Deaths n (%)
Total hsTnT
>14 ng/L
(%)
hsTnT
≤14 ng/L
(%)
Abdominal 254 (26) 10 (3.9) 7/50 (14.0) 3/204 (1.5)
Vascular
surgery
252 (26) 7 (2.8) 4/81 (4.9) 3/171 (1.8)
Orthopedy/
trauma
77 (8) 1 (1.3) 1/23 (4.3) 0/54 (0)
Gynaecology 110 (11) 1 (0.9) 1/9 (11.1) 0/101 (0)
Others 286 (29) 6 (2.1) 3/70 (4.3) 3/216 (1.4)
Distribution of the different types of surgery performed on the patients included
into the study and mortality rates.
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High-sensitive troponin T values according to comorbidities are
depicted in Table 3.
For the entire population, NT-proBNP was at median 171 pg/
mL (IQR: 79–439) and hsTnT was 7 ng/L (IQR 3–14). Both
markers were higher in those patients who died during hospitaliza-
tion when compared with those who survived [NT-proBNP 576
(271–2119) vs. 166 (77–428) pg/mL; P, 0.001 and hsTnT 21
(12–33) vs. 7 (3–13) ng/L; P, 0.001]. In the entire cohort, 335
(34%) patients had a NT-proBNP serum concentration .300 pg/
mL and 233 (24%) patients had hsTnT ≥14 ng/L. The occurrence
of the combined endpoint was strongly related to elevated
NT-proBNP (≥300 pg/mL), elevated hsTnT (.14 ng/L), and the
Lee index (Figure 1A). Comparable results could be observed for
in-hospital mortality (Figure 1B).
The ROC curves of hsTnT, NT-proBNP, and the Lee index as
predictors for the combined endpoint and for in-hospital mortality
showed a significant AUC for all parameters, with the highest AUC
for hsTnT of 0.784 for the prediction of the combined endpoint
and of 0.809 for the prediction of in-hospital mortality. Comparing
the AUC of Lee index, hsTnT, and NT-proBNP, we found no dif-
ference between NT-proBNP and the Lee index but a significant
higher AUC of hsTnT compared with the Lee index for the predic-
tion of mortality. However, for the combined endpoint, the AUC
for hsTnT was larger but this difference did miss statistical signifi-
cance. (Figure 2A and B).
Univariate Cox regression analysis revealed that the Lee index
as well as NT-proBNP and hsTnT were significantly associated
with an increased risk for the combined endpoint and for
in-hospital mortality if entered as dichotomized variable (Table 4).
In a multivariate Cox regression analysis, hsTnT .14 ng/L was
the strongest independent predictor for the combined endpoint
as well as for in-hospital mortality. In contrast, NT-proBNP and
the Lee index lost its value as an independent risk predictor
(Table 5).
HsTnT .14 ng/L was significantly associated with a higher event
rate in each risk category according to the Lee index (Figure 3A
and B).
The length of hospital stay was significantly longer in those
patients with a higher Lee index (8 vs. 11 vs. 13 days; P, 0.001)
and in patients with elevated hsTnT (10 vs. 12 days; P, 0.001). In-
tensive care treatment post-operatively was necessary in 351
patients (36%). The number of patients requiring intensive care
treatment was higher in patients with elevated NT-proBNP, with
elevated hsTnT, and was related to the Lee index (Figure 4).
Discussion
In the present study, we aimed to analyse the additive value of the
cardiac marker hsTnT in addition to the revised cardiac index (Lee
index) and NT-proBNP to identify patients at a high risk for
adverse cardiac events undergoing major non-cardiac surgery.
The key finding is that both cardiac markers provide predictive
information for the occurrence of serious clinical events, which
is incremental to that obtained by the established and most
widely applied clinical risk score, the revised cardiac risk index.8
However, hsTnT was the strongest independent risk predictor.
Furthermore, we found that pre-operative levels of both cardiac
markers were associated to the length of hospital stay and the
necessity of intensive care treatment.
Pre-operative risk assessment is of great clinical importance. In
most cases non-cardiac surgery is performed as an elective pro-
cedure allowing thorough investigation of the patient and accurate
risk evaluation in order to indicate a surgical procedure. Several
situations need to be distinguished. First, a patient undergoes non-
cardiac surgery for a prognostic indication. In this scenario, the
benefit of surgery and the associated risk need to be counterba-
lanced. Secondly, a patient undergoes non-cardiac surgery for a
symptomatic indication. In this situation, the patient needs to be
informed about his individual risk of the procedure to be able to
sign an informed consent. Thirdly, a patient unavoidably requires
surgery for a vital indication. In this case, risk assessment is of
minor interest. However, in high-risk patients the question might
arise in how far the cardiac risk can be attenuated by specific
means. Therefore, in all cases precise risk stratification is essential.
Within the last decades, several risk indices based on observa-
tional data have been introduced. Currently, the most widely
accepted risk index for patients undergoing non-cardiac surgery
is the revised cardiac risk index.8 It has been developed from pro-
spectively collected data from a total of 4315 patients divided into
a derivation and a validation cohort. The Lee index can be calcu-
lated from six clinical and easily achievable variables providing a
score from 0 to 6 points. In the original description, the incidence
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 High-sensitive troponin T values according to
comorbidities
hsTnT (ng/L)
Median IQR P-value
Creatinine .1.2 mg/dL
Yes 16 8–33 ,0.001
No 6 3–12
History of CAD
Yes 11 5–20 ,0.001
No 6 3–12
Diabetes mellitus
Yes 8 4–17 0.002
No 7 3–13
Active smoker
Yes 7 3–14 0.698
No 7 3–13
Hypertension
Yes 7 3–14 0.218
No 6 3–15
Age .65 years
Yes 9 4–17 ,0.001
No 3 3–8
Obese (BMI .27)
Yes 6 3–12 ,0.001
No 8 3–16
Values of high-sensitive troponin T according to various comorbidities.
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of major cardiac complications has been reported as being strongly
associated to the revised Lee index both, in the derivation and in
the validation cohort. In our study, which included a comparable
subset of patients, we also found a strong and stepwise association
of adverse cardiac events to the revised cardiac index, confirming
these previous data.
Several studies published within the last years have demon-
strated a prognostic value of pre-operative BNPs levels for
cardiac events in patients undergoing non-cardiac surgery.15,16 In
all of these studies, BNP or NT-proBNP was independently asso-
ciated with an increased risk. Whereas all the studies adjusted for a
variety of clinical factors, only in one of the studies the revised
cardiac index was included in the multivariate analysis. In three
other studies, either the Goldmann index or the ASA score has
been added to the analyses. Our data further confirm these
previous data demonstrating a significant association between
Figure 1 The frequency of the combined endpoint (A) and in-hospital mortality (B) in association to NT-proBNP (light grey bars), hsTnT
(grey bars), and the revised cardiac index ‘Lee index’ (dark grey bars).
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NT-proBNP and peri- and post-operative cardiac events which
was incremental to the revised cardiac index.
However, in none of those previously published studies, a com-
parative analysis with pre-operative troponin assessment has been
performed. In fact, there are no available data evaluating pre-
operative troponin testing as a predictor for post-operative
cardiac events in non-cardiac surgery. There are only data available
from three smaller studies which evaluated the value of post-
operative troponin testing, consistently demonstrating that patients
with elevated troponin after non-cardiac surgery were at a higher
risk for subsequent cardiac events.17,18
With the introduction of a new generation of high-sensitive
assays, much lower troponin concentrations are detectable with
sufficient analytical precision. With those assays, troponins are
measurable also in apparently healthy individuals. Furthermore,
low-level elevation of troponins is detectable in patients with car-
diovascular diseases other than acute coronary syndromes, provid-
ing strong prognostic information.13,14,19,20 Thus, the detection of
low-level troponin elevation, which is indicative for minor myocar-
dial damage, in apparently stable patients and non-acute subjects
suggests a potential new indication of troponins as a risk indicator
in other clinical scenarios besides acute coronary syndromes.
Figure 2 ROC curves of NT-proBNP, hsTnT, and the revised cardiac index ‘Lee index’ for the combined endpoint (A) and in-hospital
mortality (B).
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In our study, we were able to evaluate pre-operative assess-
ment of hsTnT as a risk indicator for subsequent adverse
cardiac events in a cohort of stable patients undergoing non-
cardiac surgery. Applying a cut-off value of 14 ng/L which is
equivalent to the 99th percentile of a healthy population and
which is recommended for the diagnosis of myocardial infarction
according to the universal definition of myocardial infarction, we
found elevated levels in one-fourth (24%) of the entire cohort.
However, in those patients who died, elevated levels were
found in two-thirds (64%) of the patients. Pre-operatively
hsTnT levels elevated above this cut-off were associated with a
2.6-fold increase in in-hospital mortality, acute myocardial infarc-
tion, cardiac arrest or ventricular fibrillation, cardio-pulmonary
resuscitation, and acute decompensated heart failure, and
proved to be the strongest predictor, superior to the revised
cardiac index and to NT-proBNP, for an adverse outcome after
non-cardiac surgery. Therefore, hsTnT was the best parameter
to identify a subset of individuals at extremely high risk for
peri- or post-operative adverse cardiac events. The clinical impli-
cations, however, are uncertain. We might speculate that applying
hsTnT to risk stratification, we will be able to identify those
patients who are at a high risk and who benefit from risk reduc-
tion strategies. This hypothesis, however, needs to be tested in
prospective interventional studies.
This study has several limitations with respect to the endpoint
assessment. We did not have an independent endpoint committee
which adjudicated the respective endpoints. However, since the
most frequent endpoint was all-cause mortality and the results
for the single endpoint all-cause mortality and the combined end-
point were very similar, the risk of a systematic error is negligible,
especially since all investigators were blinded to biomarker results.
Because of the study design the results are applicable only to
patients undergoing non-cardiac surgery with at least one cardio-
vascular risk factor and may not be generalizable to subjects
without any cardiovascular risk factor undergoing non-cardiac
surgery. We might have missed some myocardial infarctions
since we did not perform assessment of cardiac markers post-
operatively. Since the results of NT-proBNP and hsTnT were
not available for the investigators, a systematic bias is most unlikely.
In the current guidelines of the ESC on pre-operative cardiac
risk assessment, it is outlined that risk reduction strategies, includ-
ing pharmacological interventions or non-invasive imaging, should
be reserved for patients with high risk. Furthermore, the applica-
tion of the Lee index for cardiac risk stratification receives a
class I A recommendation in these guidelines. In the present
study, we were able to demonstrate that adding hsTnT assessment
to the Lee index, peri-operative risk stratification can be improved
substantially. Therefore, it can be speculated that hsTnT is highly
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 4 Univariate Cox regression analyses
B Wald P-value HR 95% CI
Lower Upper
hsTnT .14 ng/L 1.32 14.66 0.0001 3.73 1.90 7.31
Lee score ≥2 1.04 9.65 0.0019 2.84 1.47 5.48
NYHA class II–V 0.85 6.44 0.0112 2.35 1.21 4.53
Systolic blood pressure (mmHg) 20.02 5.73 0.0166 0.98 0.97 1.00
Heart rate (/min) 0.03 5.60 0.0180 1.03 1.00 1.05
Pre-existing coronary artery disease 0.78 5.33 0.0210 2.17 1.12 4.20
Pre-treatment with ASS or clopidogrel 0.76 4.73 0.0297 2.13 1.08 4.23
NT-proBNP .300 pg/mL 0.72 4.47 0.0345 2.05 1.05 3.99
Angina pectoris CCS II– IV 0.67 2.96 0.0851 1.94 0.91 4.15
Univariate Cox regression analyses of various variables as a predictor for the combined endpoint of mortality, acute myocardial infarction, cardiac arrest or ventricular fibrillation,
cardio-pulmonary resuscitation, and acute decompensated heart failure. Depicted are all variables with a P-value ,0.1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Multivariate Cox regression analyses
B Wald P-value HR 95% CI
Lower Upper
hsTnT .14 ng/L 0.96 6.86 0.0088 2.60 1.27 5.31
Lee score ≥2 0.64 3.04 0.0812 1.89 0.92 3.88
Systolic blood pressure (mmHg) 20.01 1.41 0.2347 0.99 0.98 1.01
NYHA class II– IV 0.62 3.12 0.0774 1.87 0.93 3.73
Multivariate Cox regression analyses for the combined endpoint of mortality, acute myocardial infarction, cardiac arrest or ventricular fibrillation, cardio-pulmonary resuscitation,
and acute decompensated heart failure adjusted for the four strongest variables with P, 0.1 in the univariate analyses.
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valuable to assign patients to an appropriate and individualized risk
reduction strategy more accurately. However, these preliminary
data need to be confirmed in further studies.
Conclusion
In the present study, we were able to demonstrate that the assess-
ment of hsTnT adds incremental prognostic information to the
established revised cardiac index (Lee index) and NT-proBNP.
The assessment of hsTnT in addition to the revised cardiac
index and NT-proBNP prior to non-cardiac surgery denotes an
easily attainable method to achieve improved pre-operative risk
stratification.
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Purulent pericarditis caused by a bad tooth
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A 14-year-old male was admitted for chest dis-
tress. Eight days ago, he picked his decayed
tooth and experienced bleeding (Panel A, the
arrow points to the bad tooth). An expansile
submaxillary mass, diagnosed as cellulitis,
appeared in 2 days (Panel B, CT showing the
mass). Antibiotics were started and operative
drainage was adopted (Panel C). But there was
little improvement in the patient’s condition
and he began feeling chest distress. An echocar-
diogram showed much fluid in the pericardial
cavity (Panel D). Ultrasound-guided percutan-
eous centesis was performed, and 1000 mL of
pericardial pus was drained. The pus was sent
for testing. Streptococcus anginosus was cultured,
which was sensitive to vancomycin. Three days
after vancomycin treatment, the amount of
drained liquid decreased significantly. But another
echocardiogram showed that there was still much
pericardial pus. Another centesis was done, but
unfortunately, the drainage tube lacerated the
heart (Panel E, the right and left arrow points to
the first and second drainage tube, respectively;
Panel F, CT showing the thickened pericardium
and drainage tubes).
During operation, lots of pus effused from
communicated pretracheal space and retro-
sternal space. After the dropsical and thickened pericardium was cut open, considerable purulent secretion mixed with cellulose ex-
udation was seen attached to the external surface of the heart (Panel G). The pus was cleared carefully, and most of the pericardium
was cut off to release the heart. After the drainage tube, which pricked into the right ventricle, was pulled out, the injured heart was
sutured. The pericardial cavity was washed with iodophors and normal saline at the end (Panel H). The patient tolerated the procedure
well and was discharged after another 2 weeks of treatment with vancomycin. The occurrence of pericarditis owing to teeth problems
is very rare. Moreover, purulent pericarditis caused by Streptococcus anginosus is also a rare.
Panels A–H. LV, left ventricle; RV, right ventricle; PS, pericardial space.
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